Effect of Repeated Administration of Liraglutide on Insulinogenic Indices
|ClinicalTrials.gov Identifier: NCT02089256|
Recruitment Status : Completed
First Posted : March 17, 2014
Last Update Posted : April 1, 2015
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: Liraglutide||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effect of Repeated Administration of Liraglutide on Insulinogenic Indices|
|Study Start Date :||June 2014|
|Actual Primary Completion Date :||March 2015|
|Actual Study Completion Date :||March 2015|
Liraglutide 0.6 mg/day subcutaneously.
Graded glucose infusion test (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated.
GGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection).
Other Name: Victoza
- Change in the glucose-sensitivity of the beta cells [ Time Frame: baseline, first dose, after 3-weeks on treatment ]Graded glucose infusion test will be used to create insulin secretion rate- plasma glucose curve. The primary outcome is the change of the slope of the curve from baseline after acute administration of liraglutide compared to the repeated administration (after 3-weeks of treatment).
- Effects on adrenal hormones [ Time Frame: baseline, acute administration, 3 weeks ]change in ACTH/cortisol levels and renin / aldosterone levels after acute and repeated administration of liraglutide.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02089256
|Tartu University Hospital|
|Principal Investigator:||Vallo Volke, MD||Tartu University|